Neurobiological Technologies Inc represents a commitment to advancing neuroscience research and providing innovative solutions. The company values scientific rigor, collaboration, and the pursuit of excellence in developing groundbreaking therapies. With a focus on neurological disorders, Neurobiological Technologies Inc aims to improve patients' quality of life and address unmet medical needs. By leveraging cutting-edge technology and a dedicated team of experts, the company strives to push the boundaries of scientific knowledge and create value for its stakeholders. Neurobiological Technologies Inc's corporate philosophy centers around delivering transformative solutions that positively impact the lives of individuals affected by neurological conditions.

Neurobiological Technologies Inc is primarily present in the United States.

Neurobiological Technologies Inc has achieved several significant milestones. Firstly, the company successfully developed and received FDA approval for a novel treatment for Parkinson's disease, XERECEPT®. This marked a major breakthrough in managing the symptoms of the disease. Additionally, Neurobiological Technologies Inc has made significant strides in the research and development of innovative neurological therapies. Their commitment to advancing science and improving patient outcomes has positioned them as a leader in the field of neurobiology. As Neurobiological Technologies Inc continues to innovate and collaborate, the company is poised to achieve even more significant milestones in the future.

Neurobiological Technologies Inc. is a biopharmaceutical company specializing in the development of innovative therapies for neurological disorders. Founded in 1982, the company has established itself as a leader in the neurology field. Throughout its history, Neurobiological Technologies Inc. has focused on researching and developing novel treatments for conditions such as Alzheimer's disease and Parkinson's disease. They have made significant contributions to the understanding of neurobiology and have garnered recognition for their pioneering work. By utilizing cutting-edge technology and scientific expertise, Neurobiological Technologies Inc. continues to make strides in improving the lives of patients affected by neurological disorders.

The main competitors of Neurobiological Technologies Inc in the market include companies such as Biogen Inc., Eli Lilly and Company, and Pfizer Inc.

Neurobiological Technologies Inc is primarily active in the pharmaceutical and biotechnology industries.

Neurobiological Technologies Inc (NTI) is a biopharmaceutical company with a focus on the research, development, and commercialization of innovative therapies for neurological diseases. NTI aims to address unmet medical needs in the field of neurology by developing novel treatments and diagnostics. Their business model revolves around conducting research to identify potential drug candidates, conducting preclinical and clinical trials, seeking regulatory approvals, and commercializing their products. By leveraging their expertise in neurobiology, NTI strives to enhance the quality of life for patients suffering from neurological disorders.

KGV-d ei saa praegu Neurobiological Technologies jaoks arvutada.

KUV-d ei ole võimalik hetkel Neurobiological Technologies jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Neurobiological Technologies on 4/10.

Praegu ei saa Neurobiological Technologies käivet arvutada.

Praegu ei ole võimalik kasumit Neurobiological Technologies jaoks arvutada.

Neurobiological Technologies Inc. (NTI) is a pharmaceutical company that focuses on researching and developing therapies for neurological disorders. The company was founded in 1987 and is headquartered in Emeryville, California. NTI's main focus is on the development of therapies for brain disorders such as Parkinson's, Alzheimer's, stroke, and epilepsy. The company has a wide range of products, including diagnostic tests and medications. One important focus of NTI is the research of technologies that can improve the diagnosis and treatment of neurological disorders. The company has built strong expertise in this field, including the use of MRI and PET scans to visualize the structure and function of the brain. One of NTI's key areas is the research and development of medications. The company has a wide range of drugs in development, including a compound called XERECEPT, which is used to treat brain tumors. XERECEPT has already been approved by the US Food and Drug Administration (FDA) and is currently being marketed through a distribution partnership with the biotechnology company Tri-Link BioTechnologies Inc. NTI has also developed a portfolio of diagnostic tests specifically designed to detect neurodegenerative diseases such as Parkinson's and Alzheimer's. These tests use various methods to detect biochemical markers in blood or cerebrospinal fluid that may indicate the presence of neurodegenerative diseases. In addition to core research and development, NTI also engages in partnerships and collaborations with other companies and organizations. This allows the company to effectively utilize its expertise in research and development and exchange resources and knowledge to develop better solutions for patients with neurological disorders. Overall, NTI strives to develop innovative therapies for neurological disorders that can improve the lives of patients worldwide. The company has strong research and development capabilities and works closely with partners and scientists to develop better solutions for the diagnosis and treatment of neurology patients.

Neurobiological Technologies maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Neurobiological Technologies jaoks arvutada või ettevõte ei maksa dividende välja.

Neurobiological Technologies ISIN on US64124W3043.

Neurobiological Technologies WKN on A0M1WB.

Neurobiological Technologies tähis on NTII.

Viimase 12 kuu jooksul maksis Neurobiological Technologies dividendi suuruses 0,93 USD . See vastab ligikaudu 930 000,00 % dividenditootlusele. Järgneva 12 kuu jooksul maksab Neurobiological Technologies tõenäoliselt dividendi summas 0,93 USD.

Neurobiological Technologies praegune dividenditootlus on 930 000,00 %.

Neurobiological Technologies maksab kvartaalset dividendi. See makstakse välja kuudel .

Neurobiological Technologies maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0,93 USD. See vastab dividenditootlusele 930 000,00 %.

Neurobiological Technologies on liigitatud sektorisse '—'.

Viimase Neurobiological Technologies dividendide saamiseks 27.12.2012 suuruses 0,05 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 18.12.2012.

Viimane dividendimakse toimus 27.12.2012.

Aastal 2023 maksis Neurobiological Technologies 0 USD dividende.

Neurobiological Technologies dividendid makstakse välja USD.